The epidemiological backdrop underscores the urgency of this research: nearly 40 percent of adults in the United States suffer from obesity, and approximately one in three individuals over the age of 70 experience some form of age-related memory loss. Despite these staggering statistics, therapeutic interventions for memory decline remain limited, largely because the biological pathways driving these changes are not fully understood. Jarome’s laboratory explores whether obesity hastens the aging process in the brain, identifying common molecular signatures that might underlie both conditions.

Central to this investigation is a ubiquitin-dependent signaling modification known as K63 polyubiquitination. This post-translational modification regulates protein function and trafficking critical to synaptic plasticity during learning and memory formation. Intriguingly, Jarome’s previous work revealed that K63 polyubiquitination activity dysregulates with age: whereas in younger brains K63 levels dynamically decrease during learning to facilitate memory encoding, in older brains these levels remain abnormally elevated, suggesting a maladaptive failure to regulate synaptic function.

To probe causality, Jarome’s team employed gene-editing tools that selectively reduce K63 polyubiquitination. Remarkably, this intervention in aged rodent models restored memory performance, demonstrating that excessive K63 activity is not merely correlative but functionally contributory to memory impairments. This insight opened new avenues for targeting molecular processes that underpin cognitive decline, particularly those exacerbated by aging.

Expanding their focus, the researchers examined the effects of a high-fat diet on younger rats to model obesity-induced cognitive deficits. The outcomes were striking: obese rats exhibited elevated K63 polyubiquitination levels comparable to those in much older animals, coupled with significant memory impairments. These findings suggested that obesity may induce premature brain aging through the same molecular mechanisms observed in natural aging, effectively accelerating synaptic dysfunction and cognitive decline on a compressed timeline.

This unexpected convergence of molecular pathways implicated in both obesity and aging underscores the potential of K63 polyubiquitination as a unifying mechanism. If obesity-induced and age-related memory loss share this pathway, then targeting K63 regulation could represent a novel therapeutic strategy to mitigate the risk of dementia. This hypothesis promises a profound shift in how neurodegenerative risk factors are conceptualized and treated.

In Jarome’s forthcoming longitudinal study, young rats will be monitored from early adulthood through senescence while receiving either a standard or high-fat diet. This design aims to delineate temporal patterns of memory decline alongside dynamic changes in protein modification profiles. By employing precise CRISPR-based gene editing to reduce K63 levels before obesity onset, the team seeks to establish whether modifying this pathway can preempt or delay memory deficits linked to both excessive weight and aging.

The implications of this research extend far beyond rodent models. Molecular targets like K63 polyubiquitination could pioneer a new class of therapeutics designed to slow or prevent cognitive decline before irreversible neurodegeneration sets in. Such interventions would be transformative across aging populations worldwide, especially as obesity rates continue to climb and life expectancy lengthens.

Professor Jarome emphasizes the translational promise: “Understanding the mechanistic overlap between obesity and brain aging points us to specific biochemical targets. Our hope is to develop interventions that slow down this accelerated aging process, thereby reducing the prevalence and impact of dementia and Alzheimer’s disease.” His work exemplifies how dissecting fundamental molecular biology can reshape clinical strategies in neurology.

This synthesis of metabolic and neurobiological research highlights the importance of integrating diverse scientific domains to tackle complex diseases. The intersection of neuroscience, molecular biology, and metabolic health reveals novel insights into cognitive impairment’s etiology and opens pathways for multidisciplinary approaches to treatment and prevention.

As the research progresses, it invites a broader reevaluation of lifestyle and pharmacological guidelines for brain health. Targeting molecular aging signatures altered by obesity could complement current measures aimed at controlling weight and metabolic syndrome, providing a dual approach to preserve cognition across the lifespan.

With a significant grant from the National Institute on Aging fueling these investigations, Professor Jarome’s lab stands at the forefront of a new frontier. Unlocking the molecular crosstalk between obesity and neural aging may ultimately yield critical breakthroughs capable of delaying or preventing the devastating effects of memory loss disorders and neurodegeneration.

In summary, the emerging evidence from Jarome’s research underscores a pivotal connection rooted in K63 polyubiquitination — one that links the metabolic state induced by obesity with accelerated brain aging and memory decline. This discovery not only advances our understanding of dementia risk but also lays the groundwork for innovative therapeutic strategies aimed at preserving cognitive health in an aging and increasingly obese global population.

Subject of Research: Molecular mechanisms linking obesity to accelerated brain aging and memory decline

Article Title: Obesity Accelerates Brain Aging via Dysregulated K63 Polyubiquitination: Insights from Virginia Tech Neuroscience Research

News Publication Date: 2024

Web References:

• https://news.vt.edu/articles/2024/01/cals-jarome-SCHEV-award.html
• https://news.vt.edu/articles/2025/10/cals-jarome-improving-memory.html
• https://sas.vt.edu/people/faculty/jarome-timothy.html

Image Credits: Photo by Marya Barlow for Virginia Tech

Keywords: neurodegeneration, obesity, memory decline, K63 polyubiquitination, aging brain, dementia, Alzheimer’s disease, cognitive disorders, CRISPR gene editing, molecular neuroscience

Memory formation, particularly of aversive or fear-inducing events, relies on highly orchestrated cellular and molecular processes within the brain. These processes are influenced by synaptic plasticity, gene expression, and post-translational modifications of key proteins. CDYL, a chromatin-modifying protein, has previously been implicated in gene regulation linked to neuronal development and plasticity. However, its dynamic regulation via phosphorylation and consequent impact on fear memory was largely unexplored until now. Lyu et al.’s research meticulously dissects how CDK5-mediated phosphorylation of CDYL acts as a molecular switch, modulating transcriptional outputs that underlie the encoding and retrieval of fear memories.

The experimental journey began by examining the temporal and spatial pattern of CDYL phosphorylation in response to neuronal activity elicited by fear conditioning paradigms in mice. Utilizing state-of-the-art phospho-proteomic techniques, the researchers identified a specific phosphorylation site on CDYL that is selectively modified following fear-inducing stimuli. This modification was further shown to be directly catalyzed by CDK5, a kinase with established functions in synaptic function and plasticity but now highlighted as crucial in epigenetic regulation of fear memory circuits.

Delving deeper into the molecular consequences of CDYL phosphorylation, the team employed chromatin immunoprecipitation sequencing (ChIP-seq) coupled with transcriptomic analysis in the amygdala—the brain’s fear center. Phosphorylated CDYL demonstrated altered binding affinities to specific genomic loci that modulate neuronal gene expression critical for synaptic remodeling. Through these changes, phosphorylated CDYL fine-tunes the expression of genes linked to synaptic strength and plasticity, effectively influencing the persistence and intensity of fear memory encoding.

Compelling behavioral assays complemented these molecular insights. Mice genetically engineered to express a phosphorylation-deficient mutant form of CDYL exhibited marked deficits in fear memory consolidation, underscoring this post-translational modification’s necessity. Conversely, enhancing CDYL phosphorylation pharmacologically potentiated fear memory retention, indicating a bidirectional control mechanism. These behavioral phenomena correlate strongly with altered synaptic connectivity and functional plasticity observed via electrophysiological recordings in fear-relevant neuronal circuits.

The significance of this research lies not only in elucidating a novel molecular axis for fear memory regulation but also in highlighting potential therapeutic targets. Anxiety disorders such as post-traumatic stress disorder (PTSD) and phobias hinge upon maladaptive fear memories. Modulating CDK5 activity or the phosphorylation status of CDYL could pave the way for precision interventions that recalibrate pathological fear memories without widespread cognitive disruption.

Intriguingly, CDK5 has been implicated in neurodegenerative diseases such as Alzheimer’s, where dysregulated phosphorylation cascades contribute to neuronal dysfunction. The discovery that CDK5-driven phosphorylation modulates epigenetic states governing fear memory opens a fascinating intersection between neurodegeneration, memory dysfunction, and psychiatric pathology. Future research may unravel whether targeting this pathway can ameliorate cognitive and emotional deficits across multiple neurological disorders.

From a methodological standpoint, this study showcases the power of integrating proteomics, epigenomics, and behavioral neuroscience to dissect intricate brain functions. The use of sophisticated in vivo phosphorylation mapping alongside genomic and electrophysiological approaches provides a holistic view of how intracellular signaling translates into complex behaviors. This multi-disciplinary framework sets a precedent for uncovering further post-translational mechanisms that shape learning and memory in health and disease.

One of the most striking aspects of the findings is the activity-dependence of CDYL phosphorylation, emphasizing the brain’s remarkable capacity for rapid molecular adaptation in response to external stimuli. This dynamic modulation underscores how transient biochemical events can induce lasting changes in gene expression patterns, ultimately sculpting neuronal circuits and behavioral outputs. The molecular plasticity exemplified here aligns with the broader concept of epigenetic regulation as a substrate for neurocognitive flexibility.

Given the conserved nature of CDK5 and CDYL across mammalian species, these findings raise the tantalizing possibility that similar regulatory mechanisms operate in the human brain. Investigation into human post-mortem tissues or induced pluripotent stem cell-derived neurons may validate the translational relevance and enable preclinical modeling of fear-associated pathologies. Such endeavors could revolutionize how we conceptualize and treat disorders rooted in aberrant fear processing.

The study also opens questions regarding the upstream signals that modulate CDK5 activity during fear conditioning. Calcium influx, neurotransmitter release, and neuromodulator signaling might converge on CDK5 activation, creating a complex network responsive to contextual cues and environmental factors. Disentangling these signal transduction pathways could uncover additional intervention points and refine therapeutic strategies.

Moreover, the identification of phosphorylation-deficient mutants as tools provides a powerful means to parse the functional domains of CDYL and their contribution to chromatin remodeling. Future structural biology studies could illuminate the conformational shifts induced by phosphorylation, advancing our mechanistic understanding of protein-DNA interactions in the context of memory regulation.

In the landscape of neuroscience research, the elucidation of post-translational modifications governing behavioral phenotypes represents a frontier with vast implications. The current work by Lyu and colleagues exemplifies how molecular neuroscience can bridge fundamental biology and clinical relevance, delivering insights that transcend disciplinary boundaries and impact human health at multiple levels.

As anxiety and fear-related disorders continue to impose a global health burden, innovations in decoding the molecular substrates of memory may inspire transformative approaches to treatment. The phosphorylation of CDYL by CDK5 emerges as a compelling target poised to alter the course of fear memory modulation, potentially ushering in an era of precision neuromodulation.

In summary, the intricate dance between CDYL and CDK5 unfurls a narrative of molecular precision controlling fear memory, coupling neuronal activity to epigenetic shifts and behavioral outcomes. This landmark discovery invigorates multiple research domains and charts a path toward novel therapeutic horizons for neuropsychiatric diseases marked by maladaptive fear memories.

Subject of Research: Regulation of fear memory via activity-dependent phosphorylation of CDYL by CDK5 in mice.

Article Title: Activity-dependent phosphorylation of CDYL by CDK5 regulates fear memory in mice.

Article References:
Lyu, NY., Xie, GG., Hu, ZW. et al. Activity-dependent phosphorylation of CDYL by CDK5 regulates fear memory in mice. Transl Psychiatry 15, 334 (2025). https://doi.org/10.1038/s41398-025-03568-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03568-0